IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.249
EU - Europa 12.434
AS - Asia 1.703
SA - Sud America 26
OC - Oceania 24
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 10
Totale 30.461
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.204
GB - Regno Unito 4.111
IE - Irlanda 2.565
CN - Cina 1.327
IT - Italia 1.325
SE - Svezia 1.281
UA - Ucraina 1.165
FR - Francia 732
DE - Germania 565
FI - Finlandia 333
VN - Vietnam 190
ES - Italia 122
BE - Belgio 77
IN - India 53
RU - Federazione Russa 46
TR - Turchia 43
CA - Canada 36
AU - Australia 20
HK - Hong Kong 19
NL - Olanda 17
IR - Iran 14
BR - Brasile 13
LU - Lussemburgo 12
GR - Grecia 11
JP - Giappone 11
AT - Austria 10
CZ - Repubblica Ceca 9
EE - Estonia 9
EU - Europa 9
PL - Polonia 7
RO - Romania 6
AR - Argentina 5
CL - Cile 5
ID - Indonesia 5
PA - Panama 5
TH - Thailandia 5
KR - Corea 4
MW - Malawi 4
SG - Singapore 4
SK - Slovacchia (Repubblica Slovacca) 4
BG - Bulgaria 3
BY - Bielorussia 3
CH - Svizzera 3
EG - Egitto 3
HU - Ungheria 3
IL - Israele 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CY - Cipro 2
DK - Danimarca 2
HR - Croazia 2
LT - Lituania 2
MX - Messico 2
MY - Malesia 2
PH - Filippine 2
SA - Arabia Saudita 2
SC - Seychelles 2
TW - Taiwan 2
UG - Uganda 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
A1 - Anonimo 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BW - Botswana 1
CO - Colombia 1
EC - Ecuador 1
GH - Ghana 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
ME - Montenegro 1
NC - Nuova Caledonia 1
NO - Norvegia 1
OM - Oman 1
PE - Perù 1
SI - Slovenia 1
SV - El Salvador 1
Totale 30.461
Salva come PNG Salva come JPEG
Città #
Southend 3.754
Dublin 2.532
Fairfield 2.523
Houston 1.637
Chandler 1.532
Ashburn 1.240
Woodbridge 1.132
Jacksonville 972
Seattle 931
Wilmington 927
Ann Arbor 857
Cambridge 854
Siena 544
Princeton 437
Beijing 323
Nanjing 295
Menlo Park 228
New York 201
Dong Ket 187
San Mateo 183
Boardman 162
Helsinki 150
San Diego 138
Nanchang 112
Málaga 111
Shanghai 102
Dearborn 92
Brussels 74
Rome 67
Tianjin 64
London 61
Shenyang 55
Hebei 51
Düsseldorf 48
Jiaxing 38
Changsha 36
Kunming 36
Norwalk 36
Milan 35
Bologna 34
Florence 34
Lancaster 34
Jinan 33
Falls Church 30
Fremont 29
San Francisco 29
Redwood City 28
Zhengzhou 27
Izmir 26
Hangzhou 23
Toronto 23
Ningbo 20
Mestre 17
Phoenix 17
Taizhou 17
Venezia 17
Washington 16
Guangzhou 14
Kilburn 14
Los Angeles 14
Wandsworth 13
Lappeenranta 12
Luxembourg 12
Paris 12
Lanzhou 11
Amsterdam 10
Atlanta 10
Chiswick 10
Edinburgh 10
Fuzhou 10
Hefei 10
Tappahannock 10
Ufa 10
Vienna 10
Central 9
Leawood 9
Melbourne 9
Padova 9
Tallinn 9
Changchun 8
Islington 8
Naples 8
Roccagorga 8
Turin 8
Andover 7
Bangalore 7
Chicago 7
Frankfurt am Main 7
Renton 7
Brescia 6
Canberra 6
Falkenstein 6
Hong Kong 6
Hounslow 6
Montreal 6
Redmond 6
Stockholm 6
Groningen 5
Prague 5
Saint Petersburg 5
Totale 23.586
Salva come PNG Salva come JPEG
Nome #
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 555
Surrogate markers as a guide to evaluate response to antiretroviral therapy 411
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 330
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 252
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 218
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 209
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 206
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 192
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 191
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 184
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 180
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 180
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 176
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 175
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 173
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 171
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 168
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 166
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 164
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 164
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 162
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 162
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 159
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 158
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 157
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 155
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 155
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 152
Anticipating policy considerations for a future HIV vaccine: a preliminary study 150
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 150
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 150
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 150
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 148
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 147
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 146
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 145
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 145
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 145
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 144
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 144
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 143
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 143
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 142
null 142
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 142
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 141
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 141
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 140
HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. 138
European guidelines on the clinical management of HIV-1 tropism testing 138
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 137
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. 137
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 137
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 136
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. 135
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 135
A novel methodology for large-scale phylogeny partition 135
A child with vestibular neuritis. Is adenovirus implicated? 135
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America. 135
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy. 135
null 135
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 135
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 135
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 135
Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment 134
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 134
Predicting response to antiretroviral treatment by machine learning: the EuResist project. 134
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 133
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 133
HIV-1 and human myelin proteins share an antigenic determinant 132
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 132
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 132
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 131
Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. 130
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics 130
DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018 130
Only slight impact of predicted replicative capacity for therapy response prediction 129
null 129
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 129
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 129
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 128
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 127
Biotechnology for virus vaccine design, production, and control 126
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 126
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 125
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 124
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 124
Focal myositis: a polymerase chain reaction analysis for a viral etiology 123
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 123
Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men 123
First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing 123
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 123
HIV acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir/ritonavir containing therapy 122
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 122
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 122
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 122
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 122
The global burden of HIV-1 drug resistance in the past 20 years 122
null 121
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 121
Totale 15.366
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.545
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.545 0 0 0 0 0 0 0 0 0 0 773 772
2019/20207.542 737 380 890 1.165 597 574 621 800 647 560 192 379
2020/20214.952 228 472 129 433 372 535 417 709 481 412 304 460
2021/20223.917 213 471 270 404 199 148 210 174 301 400 362 765
2022/20235.292 317 522 624 734 513 1.039 149 434 495 160 204 101
2023/20243.458 159 100 321 215 86 1.093 1.294 103 18 65 4 0
Totale 31.041